Interestingly, the PFS after ICB therapy was significantly longer in patients with altered ARID1A than in those with wildtype ARID1A, regardless of microsatellite instability (MSI) and tumor mutation burden (TMB) statuses [63]. Here, ARID1A is linked to neoplasm.